top of page
  • Writer's pictureSBIJI Innovation

Chemomab Receives RegulatoryApproval to Commence a Phase IIClinical Trial for CM-101

July 21, 2020

Chemomab Ltd., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, today announces that it has received all necessary regulatory approvals in the UK and Israel, to commence a Phase IIa clinical trial for CM-101 as treatment for Primary Sclerosing Cholangitis (PSC).

5 views0 comments

Recent Posts

See All


bottom of page